Use of antileukotriene agents in asthma management

National Asthma Education Program. Expert Panel Report II: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute; 1997. Spector SL. Leukotriene activity modulation in asthma. Drugs. 1997;54:369–384. Holgate ST, Bradding P, Sampson AP. Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy. J Allergy Clin Immunol. 1996;98:1–13. Peters-Golden M, Song K, Marshall T, Brock T. Translocation of the cytosolic phospholipase A2 to the nuclear envelope elicits topographically localized phospholipid hydrolysis. Biochem J. 1996;318:797–803. Coleman RA, Eglen RM, Jones RL, et al. Prostanoid and leukotriene receptors: a progress report from the IUPHAR working parties on classification and nomenclature. Adv Prost Throm Leuko Res. 1995;23:283–285. Barnes NC, Piper PJ, Costello JF. Comparative actions of inhaled leukotriene C4 and leukotriene D4 and histamine in normal human subjects. Thorax. 1984;39:500–504. Laitinen L, Laitinen A, Haahtela T, Vilkka V, Spur BW, Lee TH. Leukotriene E4 and granulocytic infiltration into asthmatic airways. Lancet. 1993;341:989–990. Smith LJ, Geller S, Ebright L, Glass M, Thyrum PT. Inhibition of leukotriene D4-induced bronchoconstriction in normal subjects by the oral LTD4 receptor antagonist ICI 204,219. Am Rev Respir Dis. 1990;141:988–992. O'Shaughnessy TC, Georgiou P, Howland K, Dennis M, Compton CH, Barnes NC. Effect of pranlukast, an oral leukotriene receptor antagonist on leukotriene D4 (LTD4) challenge in normal volunteers. Thorax. 1997;52:519–522. Smith LJ, Hanby LA, Lavins BJ, Simonson SG. A single dose of zafirlukast reduces LTD4-induced bronchoconstriction in patients maintenance inhaled corticosteroid therapy. Ann Allergy Asthma Immunol. 1998;81:43–49. Finnerty JP, Wood-Baker R, Thomson H, Holgate ST. Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist. Am Rev Respir Dis. 1992;145:746–749. Lazarus SC, Wong HH, Watts MJ, Boushey HA, Lavins BJ, Minkwitz MC. The leukotriene receptor antagonist zafirlukast inhibits sulfur dioxide-induced bronchoconstriction in patients with asthma. Am J Respir Crit Care Med. 1997; 156:1725–1730. Reiss TF, Hill JB, Harman E, et al. Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist. Thorax. 1997;52:1030–1035. Taylor IK, O'Shaughnessy KM, Fuller RW, Dollery CT. Effect of cysteinyl-leukotriene receptor antagonist ICI 204,219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet. 1991;337: 690–694. Hamilton A, Faiferman I, Stober P, Watson RM, O'Byrne PM. Pranlukast, a cysteinyl leukotriene receptor antagonist, attenuates allergen-induced early- and late-phase bronchoconstriction and airway hyperresponsiveness in asthmatic subjects. J Allergy Clin Immunol. 1998;102:177–183. Israel E, Fischer AR, Rosenberg MA, et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis. 1993;148: 1447–1451. Calhoun WJ, Lavins BJ, Minkwitz MC, Evans R, Gleich GJ, Cohn J. Effect of zafirlukast (Accolate) on cellular mediators of inflammation: bronchoalveolar lavage fluid findings after segmental antigen challenge. Am J Respir Crit Care Med. 1998;157:1381–1389. Hui KP, Barnes NC. Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. Lancet. 1991;337:1062–1063. Fish JE, Kemp RF, Lockey M, Glass M, Hanby LA, Bonuccelli CM. Zafirlukast improves symptomatic mild to moderate asthma: a 13-week multicenter study. Clin Ther. 1997; 19:675–690. Suissa S, Dennis R, Ernst P, Sheehy O, Wood-Dauphinee S. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1997;126:177–183. Israel E, Cohn J, Dubé L, Drazen JM, Zileuton Clinical Trial Group. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma: a randomized controlled trial. JAMA, 1996;275:931–936. Liu MC, Dubé LM, Lancaster J. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. J Allergy Clin Immunol. 1996;98:859–871. Spector SL, Smith LJ, Glass M. ‘Accolate’ Asthma Trialist Group. Effects of 6 weeks of therapy with oral doses of ICI-204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med. 1994; 150:618–623. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Arch Intern Med. 1998;158:1213–1220. Kemp JP, Glass M, Minkwitz M. Onset of action of the leukotriene-receptor antagonist, zafirlukast (Accolate®), in patients with asthma (abstr). J Allergy Clin Immunol. 1995; 95:844. Knorr B, Matz J, Bernstein JA, et al. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized double-blind trial. JAMA. 1998;279:1181–1186. Grossman J, Faiferman I, Dubb JW, et al. Results of the first U.S. double-blind, placebo-controlled, multicenter clinical study in asthma with pranlukast, a novel leukotriene receptor antagonist. J Asthma. 1997;34:321–328. Barnes NC, Pujet J-C, International Study Group. Pranlukast, a novel leukotriene receptor antagonist: results of the first European, placebo controlled, multicentre study in asthma. Thorax. 1997;52:523–527. Nathan RA, Glass M, Snader L. Thirteen weeks of treatment with zafirlukast (Accolate®) or cromolyn sodium (Intal®) in patients with mild or moderate asthma. Abstract 46. In: Asthma 95: Theory to treatment. Joint conference sponsored by the American Academy of Allergy, Asthma, and Immunology and the American Thoracic Society, Chicago, July 15–17, 1995. Schwartz HJ, Petty T, Dube LM, Swanson LJ, Lancaster JF, A randomized controlled trial comparing zileuton with theophylline in moderate asthma. The Zileuton Study Group. Arch Intern Med. 1998;158:141–146. Physicians' Desk Reference. 53rd ed. Montvale, NJ: Medical Economics Co; 1999. Barnes NC, Black B, Syrett N, et al. Reduction of exacerbation of asthma in multinational clinical trials with zafirlukast (Accolate®). Am J Respir Crit Care Med. 1996;153:A802. Nathan RA, Bernstein JA, Bielory L, et al. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. J Allergy Clin Immunol. 1998;102:935–942. Markham A, Faulds D. Montelukast. Drugs. 1998;56:251–256. Virchow J, Hassall SM, Summerton L, Harris A. Improved asthma control over 6 weeks with Accolate® (zafirlukast) in patients on high-dose inhaled corticosteroids. J Investig Med. 1997; 45:286A. Tamaoki J, Kondo M, Sakai N, et al. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. Am J Respir Crit Care Med. 1997;155:1235–1240. Donnelly AL, Glass M, Minkwitz MC, Casale TB. The leukotriene D4-receptor antagonist, ICI 204,219, relieves symptoms of acute seasonal allergic rhinitis. Am J Respir Crit Care Med. 1995;151:1734–1739. Leff JA, Busse WW, Pearlman D, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med. 1998;339:147–152. Makker HK, Lau LC, Thomson HW, Binks SM, Holgate ST. The protective effect of inhaled leukotriene D4 receptor antagonist ICI 204,219 against exercise-induced asthma. Am Rev Respir Dis. 1993;147:1413–1418. Meltzer SS, Hasday JD, Cohn J, Bleecker ER. Inhibition of exercise-induced bronchospasm by zileuton: a 5-lipoxygenase inhibitor. Am J Respir Crit Care Med. 1996;153:931–935. Pearlman DS, Ostrom NK, Bronsky EA, Bonuccelli CM, Hanby LA. The leukotriene D4 receptor antagonist zafirlukast attenuates exercise-induced bronchoconstriction in children. J Pediatr. 1999;34:273–279. Ohno S, Sugiyama Y, Kitamura S. The roles of peptido-leukotriene and thromboxane A2 in cough-variant asthma (abstr). Eur Respir J. 1997;10:439S-440S. Holloway J, Ferriss J, Groff J, Craig TJ, Klinik M. Churg-Strauss syndrome associated with zafirlukast. J Am Osteopath Assoc. 1998;98:275–278. Merck Singulair Churg-Strauss cases reported in “Dear Doctor” letter. The Pink Sheet. 1998:11. Wechsler ME, Garpestad E, Flier SR, et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA. 1998;279:455–457.